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Abstract
Background: Mutations in the gene encoding Ubiquilin-2 (UBQLN2) are linked to amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD). UBQLN2 plays a central role in ubiquitin proteasome system (UPS) and
UBQLN2 mutants can form cytoplasmic aggregates in vitro and in vivo.
Results: Here, we report that overexpression of WT or mutant UBQLN2 species enhanced nuclear factor κB (NF-κB)
activation in Neuro2A cells. The inhibition of NF-κB stress-mediated activation with SB203580, a p38 MAPK inhibitor,
demonstrated a role for MAPK in NF-κB activation by UBQLN2 species. Live cell imaging and microscopy showed
that UBQLN2 aggregates are dynamic structures that promote cytoplasmic accumulation of TAR DNA-binding
protein (TDP-43), a major component of ALS inclusion bodies. Furthermore, up-regulation of UBQLN2 species in
neurons caused an ER-stress response and increased their vulnerability to death by toxic mediator TNF-α. Withaferin
A, a known NF-κB inhibitor, reduced mortality of Neuro2A cells overexpressing UBQLN2 species.
Conclusions: These results suggest that UBQLN2 dysregulation in neurons can drive NF-κB activation and cytosolic
TDP-43 aggregation, supporting the concept of pathway convergence in ALS pathogenesis. These Ubiquilin-2
pathogenic pathways might represent suitable therapeutic targets for future ALS treatment.
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Background
Amyotrophic lateral sclerosis (ALS) is the most common
adult-onset motor neuron disorder. It is characterized by
progressive degeneration of upper and lower motor neu-
rons leading to paralysis and, unfortunately, to patient’s
death within 2 to 5 years. Nearly 10 % of ALS cases are
familial and 90 % are sporadic. Expanded hexanucleotide
repeats in C9orf72 account for approximately 30 % of
familial cases, mutations in superoxide dismutase 1
(SOD1) for 20 % whereas other genes like TAR DNA-
binding protein (TDP-43), fused in sarcoma (FUS), p62/
SQSTM1 and Ubiquilin-2 (UBQLN2) account for less
than 10 % [1]. The main pathogenic mechanisms of
ALS are still a mystery. Numerous cellular dysfunc-
tions have been linked to ALS physiopathology in-
cluding oxidative stress, protein inclusions, inflammatory
processes, RNA processing and endoplasmic reticulum
stress (ER-stress) [2].
Ubiquilin-2 acts as an important player in the ubiqui-
tin proteasome system (UPS) by connecting the UPS
and ubiquitinated proteins. It is also implicated in
autophagy, cell cycle progression and cell signaling.
UBQLN2 possesses an N-terminal ubiquitin-like do-
main, a C-terminal ubiquitin-associated domain and a
PXX domain essential for protein-protein interaction
[3]. Originally, five X-linked mutations in UBQLN2 gene
have been discovered in ALS/FTD familial cases [4]. All
these mutations are located in the PXX domain and one
of the most frequent is P497H. Patients with mutant
UBQLN2P497H develop cytoplasmic inclusions positive
for major proteins implicated in ALS such as TDP-43,
ubiquitin, FUS and p62. Furthermore, ALS/FTD patients
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without UBQLN2 mutation also express UBQLN2 posi-
tive inclusions, supporting an important role of this
protein in ALS physiopathology [4]. More than ten
UBQLN2 mutations have been currently described in
ALS, not only in the PXX domain [5–8]. UBQLN2 is
also implicated in other neurological disorders such as
FTD [4], Alzheimer’s disease [9] and Huntington’s
disease [10].
Nuclear Factor kappa-B (NF-κB) is a transcription fac-
tor implicated in inflammation. NF-κB is formed by
members of Rel/NF-κB family such as p50, p52, p65
(RelA), RelB or c-Rel in homo or heterodimeric com-
plexes. The complex composed of p65 and p50 has been
the most characterized. A wide variety of extracellular
signals lead to NF-κB activation, including cytokines, in-
fectious agents or oxidants. Almost all signals that trig-
ger the NF-κB signaling pathway converge on activation
of a molecular complex that contains a serine residue-
specific IκB kinase (IKK). In the classical (canonical)
NF-κB pathway, activation of the IKK complex leads to
phosphorylation mediated by IKKβ of IκB-α, which is
subsequently targeted for intracellular ubiquitination
and degradation by the proteasome complex. This re-
leases p65 NF-κB from IκB-α inhibitor and the phos-
phorylated p65 form is then transported to nucleus
where it binds to specific response elements (RE) affect-
ing transcription of various genes involved in a diversity
of biological processes such as immunity, inflammatory,
stress response and development [11]. NF-κB has an
emerging role in ALS or other neurological disorders.
NF-κB activity is increased in human neuroblastoma
cells expressing mutant SOD1G93A [12] and it is up-
regulated in motor neurons of sporadic ALS cases [13].
Our group reported previously that TDP-43 interacts
with NF-κB and that NF-κB mRNA levels are abnor-
mally up-regulated in the spinal cord of ALS patients
[14]. Furthermore, NF-κB inhibition by administration
of Withaferin A, a known NF-κB inhibitor, reduced ALS
disease symptoms in a TDP-43 transgenic mouse model
[14] and extended lifespan of mutant SOD1 ALS mice
[15]. Longevity of mutant SOD1 mice was also increased
by microglia-specific inhibition of NF-κB pathway [16].
These data suggest a central role for the NF-κB pathway
in ALS pathogenesis.
Here, we used a NF-κB-luciferase reporter assay to
examine the effect of UBQLN2 overexpression on
NF-κB activity. We have determined that up-
regulation of UBQLN2 enhances NF-κB activation in
Neuro2A cells. We also used small interference RNA
(siRNA) against UBQLN2 to prevent NF-κB activation
by UBQLN2. Treatment of transfected cells with dif-
ferent MAPK inhibitors suggested that NF-κB activa-
tion by UBQLN2 species resulted from p38 MAPK
activation. Moreover, we found that up-regulation of
UBQLN2 protein species causes aggregation and cyto-
plasmic accumulation of TDP-43. Evidence is presented
that UBQLN2 inclusions are dynamic structures which
can increase in size over time. Finally, we report that
UBQLN2 upregulation enhances ER-stress response and
NF-κB-mediated neuronal vulnerability to death caused
by exposure to toxic mediator TNF-α.
Results
UBQLN2 up-regulation induces NF-κB activation
We transfected Neuro2A cells with pCMV-hUBQLN2WT
and mutant pCMV-hUBQLN2P497H plasmids to deter-
mine the effects of overexpressing hUBQLN2 species on
activation of NF-κB signaling. TNF-α treatment was used
to trigger NF-κB activation and to mimic neuro-
inflammatory condition in ALS disease [17]. We detected
a NF-κB hyper-activation in Neuro2A cells overexpressing
hUBQLN2 species. Figure 1a shows a Western blot ana-
lysis of nuclear and cytoplasmic protein extracts at
48 hours after transfection. We prepared nuclear and
cytosolic fractions to assess the NF-κB distribution in
cells. According to our results, the distribution and the
phosphorylation of NF-κB p65 in Neuro2A cells is re-
quired to precisely measure NF-κB activity. As compared
to control cells, we observed a slight increase of nuclear
phospho-p65 in hUBQLN2WT-transfected cells and a
higher increase of nuclear phospho-p65 in cells trans-
fected with hUBQLN2P497H after TNF-α treatment
(Fig. 1a, b). Non-phosphorylated nuclear p65 NF-κB
was equally increased in both hUBQLN2WT and
hUBQLN2P497H. We did not observe difference in nuclear
phospho-p65 without TNF-α treatment but we observed
an increase in cytoplasmic phospho-p65 in both
hUBQLN2WT and hUBQLN2P497H transfected cells. We
also monitored IκB-α phosphorylation and degradation as
a marker of NF-κB activation. We did not observe differ-
ences in levels of phospho-IκB-α between control
cells and hUBQLN2-overexpressing cells with or with-
out TNF-α treatment. In the classical pathway of NF-κB
activation, the phosphorylation of the IκB-α protein re-
sults in its ubiquitination, dissociation from NF-κB, and
eventual degradation by the proteasome. However, it has
been reported that in Neuro2A cells treated with TNF-α,
IκB-α is phosphorylated and degraded within a short time
period (30 min) and then the levels come back to basal
level within 2 h, even if NF-κB remains activated [18]. Our
results are consistent with this report. Moreover, an
involvement of p38 MAPK in the phosphorylation and ac-
tivation of p65 as substantiated below does not require
IκB-α protein degradation.
To accurately measured the NF-κB activation, we per-
formed a luciferase reporter assay in Neuro2A cells sta-
bly transfected with pGL4.32 [luc2p/NF-κB-RE/Hygro].
This plasmid contains a NF-κB response element which
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expresses luciferase when NF-κB is activated. 24 h after
transfection and after 4 h of TNF-α (20 ng/ml) treatment,
both hUBQLN2WT and hUBQLN2P497H showed a mean
increase of 1.27 fold in luciferase activity (p < 0.0001)
(Fig. 1c). 48 h after transfection and after 4 h of
TNF-α (20 ng/ml) treatment, again both hUBQLN2WT
(p = 0.0004) and hUBQLN2P497H (p = 0.0061) expressing
cells exhibited a mean increase of 1.28 fold in luciferase
activity compare to control cells (Fig. 1d).
We used siRNA to validate the role of hUBQLN2 in
NF-κB activation. The main idea was to down-regulate
NF-κB activity by eliminating hUBQLN2 overexpression
and aggregation. Three different siRNA, purchased from
Origene (Rockville), were targeting human UBQLN2
gene. All three siRNA were efficient in down-regulating
the levels of hUBQLN2 in Neuro2A cells and in abrogat-
ing formation of inclusions (data not shown). We trans-
fected Neuro2A cells with siRNA SR309321A for 48 h.
48 h after transfection, cells were treated with TNF-α for
4 h and luciferase activity was measured. Again, we
detected an increase of NF-κB activity in both
hUBQLN2WT (1.26 fold, p < 0.01) and hUBQLN2P497H
(1.22 fold, p < 0.01) transfected Neuro2A cells as com-
pared to the control cells transfected with scrambled
siRNA. When hUBQLN2WT or hUBQLN2P497H were
co-transfected with siRNA SR309321A, luciferase activ-
ity decreased (p < 0.01) and came back to level noticed
in control plasmid transfected cells (Fig. 1e). Scrambled
siRNA do not recognize any sequences in either mouse
or human genome. We measured human UBQLN2 level
after siRNA/UBQLN2 co-transfection to assure the
down regulation of hUBQLN2 (Fig. 1f ). Endogenous
mouse UBQLN2 levels were not reduced. These results
suggest a role for hUBQLN2 in modulating NF-κB
activation.
UBQLN2 expression in Neuro2A cells leads to cellular
stress via MAP kinase pathway
We further investigated the cellular mechanisms which
might explain NF-κB activation by UBQLN2. NF-κB can
be activated by many different pathways [11]. Because
most of these pathways are induced by membrane recep-
tors, like Interleukine-1(Il-1), Toll-like receptor (TLR),
tumor-necrosis factor receptor (TNFR) and growth
Fig. 1 NF-κB activation induced by hUBQLN2 is suppressed with hUBQLN2 siRNA. Neuro2A cells were transfected with control plasmid, pCMV-
hUBQLN2WT or pCMV-hUBQLN2P497H. Cells were treated or not with TNF-α 20 ng/ml for 4 h before luciferase assay or before collecting the cells.
a Cytoplasmic (C) and nuclear (N) extraction was realized 48 h after transfection. Antibodies were use according to Materials and Methods.
b Immunoblot quantification of nuclear phospho-NF-κB p65 vs p84 nuclear matrix as compared to nuclear levels in control cells (p = 0.0426,
n = 3). c Neuro2A cells were stably transfected with pluc2p-NFκB-RE plasmid and then transfected with control plasmid, pCMV-hUBQLN2WT
or pCMV-hUBQLN2P497H. Luciferase activity (NF-κB) was measured at 24 h (s < 0.0001 for hUBQLN2WT and hUBQLN2P497H, n = 6,) and (d) at
48 h (p = 0.0004 for hUBQLN2WT and p = 0.0061 for hUBQLN2P497H, n = 3). e Cells were co-transfected with control plasmid, pCMV-hUBQLN2WT
or pCMV-hUBQLN2P497H and with hUBQLN2 siRNA or scrambled siRNA. Luciferase activity was measured at 48 h after transfection (p < 0.01,
n = 5). f Immunoblot of UBQLN2 proteins. Upper band corresponds to mouse UBQLN2 (endogenous) and lower band to human UBQLN2
(transfected). Immunoblot was showing the reduced levels of only human UBQLN2 after co-transfection with siRNA
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factor receptor (GF-R), we examined intracellular path-
ways activated in context of cellular stress. Additionally,
in Fig. 1, Neuro2A cells required to be stimulated by
TNF-α to detect a significant NF-κB activation induced
by UBQLN2 up-regulation. These results suggest an in-
volvement of TNF-α downstream pathway. We hypothe-
sized that UBQLN2 up-regulation might constitute a
cellular stress which may increases levels of MAP ki-
nases and enhances their activation by TNF-α. TNF-α
receptor cascade activates numerous of signaling path-
ways, including p38 MAPK, p42/44 MAPK (ERK) and
JNK/SAPK [19]. Each of these pathways can be activated
by other mechanisms. JNK and p38 are mainly activated
by cellular stress, such as inflammatory cytokines, UV,
radiation, protein synthesis inhibitor, oxidative stress or
ER-stress [20, 21] . ERK is more activated by growth fac-
tor, reactive oxygen species (ROS), ER-stress [22] and is
also implicated in differentiation, memory and synaptic
plasticity [23, 24]. All these kinases are implicated in
NF-κB activation, making them suitable candidate for
NF-κB activation by UBQLN2 [19].
To investigate if any of these pathways were activated
by hUBQLN2, we transfected Neuro2A cells with
control plasmid, pCMV-hUBQLN2WT and pCMV-
hUBQLN2P497H. We detected an increase in levels of
phosphorylated MAPK in hUBQLN2 overexpressing
cells. Figure 2a is showing the levels of these phosphory-
lated proteins (activated form) 48 h after transfection.
Fig. 2 hUBQLN2 expression in Neuro2A cells caused cellular stress via MAP kinase pathway. a Cytoplasmic (C) and nuclear (N) extraction was
realized 48 h after transfection. Neuro2A cells were treated with TNF-α 20 ng/ml for 4 h. b Hypothetical model of NF-κB activation by hUBQLN2.
p38 MAPK seems to be a major player in this activation. c Quantification of cytosolic phospho-p42/44 MAPK vs non-phosphorylated p42/44 MAPK
(p = phospho)(n = 3), (d) cytosolic phospho-p38 vs non-phosphorylated p38 MAPK (p = 0.0051 for hUBQLN2WT and p < 0.05 for hUBQLN2P497H,
n = 3) and (e) cytosolic phospho-JNK vs non-phosphorylated JNK MAPK (n = 3) as compared to cytoplasmic level in control cells. f Neuro2A cells
were pre-treated 1 h with MAPK inhibitors 10 μM U0126-EtOH, SB203580, SP600125 and then treated with TNF-α 20 ng/ml for 4 h. Total protein
extract was used for analysis. g Luciferase assay showing control plasmid, pCMV-hUBQLN2WT and pCMV-hUBQLN2P497H transfected Neuro2A cells.
Cells were pre-treated 1 h with MAPK inhibitors 10 μM U0126-EtOH, SB203580, SP600125 and then treated with TNF-α 20 ng/ml for 4 h (n = 3).
h Previous (g) luciferase activity was calculated in percentage of control Neuro2A cells, treated with SB203580 or not
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The levels of phospho-p42/44 MAPK were not different
in cells expressing hUBQLN2WT and hUBQLN2P497H as
compared to control cells after TNF-α treatment
(Fig. 2c). Moreover, there was a clear and significant in-
crease of phospho-p38 in hUBQLN2WT (p = 0.0051) and
hUBQLN2P497H (p < 0.05) transfected cells treated with
TNF-α (Fig. 2d). However, we did not observed any in-
crease in phospho-JNK/SAPK level compared to control
(Fig. 2e). From these results, we can propose that
UBQLN2 up-regulation leads to cellular stress via
MAPK pathway.
To further elucidate which MAPK pathway is impli-
cated in NF-κB activation by UBQLN2, we treated the
cells with different specific MAPK inhibitors. Luciferase
activity was measured at 1 h after inhibitor pre-
treatment and after 4 h of TNF-α treatment. We used
U0126-EtOH, a selective p42/44 MAPK inhibitor,
SB203580, a p38 MAPK inhibitor and SP600125, a se-
lective JNK1/2/3 inhibitor. In comparison with U0126-
EtOH which was specific to p42/44 MAPK inhibition,
SP600125 and SB203580 also partially inhibited p42/44
MAPK at a lower level than U0126-EtOH (Fig. 2f ). We
observed that all three kinase inhibitors led to partial
decrease of NF-κB activity by the inhibition of their spe-
cific MAPK (Fig. 2f-g). After treatment with U0126-
EtOH, we determined that NF-κB activity, as compared
to control cells, was still significantly increased in
hUBQLN2WT (1.46 fold, p < 0.0001) and hUBQLN2P497H
(1.38 fold, p < 0.0001) transfected cells (Fig. 2g). Conse-
quently, treating the cells with U0126-EtOH failed to in-
hibit UBQLN2-mediated NF-κB activation observed
with TNF-α treatment alone (Figs. 1, 2g). We obtained
almost the same results with SP600125 treatment. When
Neuro2A cells were treated with this JNK inhibitor, there
was still an increase of NF-κB activity in cells transfected
with hUBQLN2WT (1.21 fold, p = 0.0034) or with
hUBQLN2P497H (1.20 fold p = 0.0301) as compared to
control cells. However, after treatment with SB203580,
the NF-κB activity became similar between control
cells and cells transfected with hUBQLN2WT (1.09
fold, p = 0.1052) or hUBQLN2P497H (1.09 fold, p = 0.1690)
(Fig. 2g). When measured using percentage of control,
NF-κB activity after SB203580 treatment was reduced by
19.2 % in hUBQLN2WT cells (p = 0.0038) and 18.7 % in
hUBQLN2P497H (p = 0.0289) (Fig. 2h). These results
suggest that p38, but not p42/44 or JNK, was involved
in enhancement of NF-κB activation by UBQLN2 up-
regulation.
UBQLN2 promotes aggregation of ALS-linked proteins
and cytoplasmic mislocalization of TDP-43
We investigated a potential involvement of protein ag-
gregation in cellular stress due to UBQLN2 expression.
Protein inclusions are a pathological hallmark of ALS
and other neurological disorders. Proteins such as TDP-
43, SOD1, P62 and FUS are components of these aggre-
gates [25]. It has been shown with Neuro2A cells that
co-transfection of UBQLN2 and c-terminal domain of
TDP-43 cause aggregates of both proteins and that
UBQLN2 seem to be more prone to aggregation than
TDP-43 [4]. Furthermore, UBQLN2P506T co-localize with
TDP-43 when injected in mouse with rAAV2/8 [26], but
not in UBQLN2P497H transgenic mouse [27] or in
UBQLN2P497H transgenic rats [28]. To elucidate this in-
constancy and to clarify if hUBQLN2 aggregates can
promote aggregation of endogenous TDP-43, we used
different biochemical methods. First, we transfected
Neuro2A cells with pCMV-hUBQLN2WT or pCMV-
hUBQLN2P497H to determine if inclusions were formed
and if they exhibited ALS-like features with aggregated
TDP-43 or p62 proteins and if positive for NF-κB as-
sociated proteins. Immunofluorescence microscopy re-
vealed co-localization of UBQLN2, TDP-43 and p62
(as expected), but not co-localization of NF-κB p65
or IκB-α (Fig. 3b-c). Similar results were obtained
when transfected cells were treated with TNF-α (data
not shown). These data suggest the lack of direct
interaction between UBQLN2 and NF-κB or IκB-α.
UBQLN2 aggregation triggered a mislocalization of
endogenous TDP-43 from nucleus to cytoplasm. Ana-
lyses of cytoplasmic and nuclear extracts revealed an in-
crease in cytoplasmic TDP-43 in both hUBQLN2WT and
hUBQLN2P497H transfected cells compare to control, at
48 h after transfection (Fig. 3h). To further confirm the
formation of aggregates, we have fractionated the soluble
and insoluble proteins. There was significant increase of
TDP-43 and p62 levels in insoluble fraction of
hUBQLN2-expressing cells as compared to control cells
(Fig. 3d, e, f ). There was no increase of NF-κB or IκB-α
in the insoluble fraction of UBQLN2 cells. To examine if
the cytosolic mislocalization of TDP-43 by UBQLN2 is
time dependent, we performed live imaging of Neuro2A
cells co-transfected with pFeGFP-hUBQLN2P497H and
DsRED-TDP-43. We noted that at 24 h after transfec-
tion, TDP-43 was localized in the nucleus whereas
UBQLN2P497H was detected in cytoplasmic inclusions.
However, at 48 h after transfection, TDP-43 was co-
localized with UBQLN2-positive inclusions (Fig. 3g). To
assess whether the expression levels of hUBQLN2 in
transfected Neuro2A were of physiological relevance, we
compared the levels of UBQLN2 in transfected and non-
transfected Neuro2A cells with UBQLN2 levels in non-
transfected and transfected HEK293 cells. The immuno-
blotting results revealed that levels of hUBQLN2 in
transfected Neuro2A cells were not in excess of en-
dogenous mouse ubiquilin-2 levels or of endogenous
human UBQLN2 levels in HEK293 cells (Fig. 3i). So, this
suggests that small changes in UBQLN2 levels are
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sufficient to promote cytosolic co-aggregation of
UBQLN2, TDP-43 and p62. It should be noted that we
did not detect TDP-43 aggregates in Neuro2A cell over-
expressing only CMV-TDP-43 vector (Additional file 1).
UBQLN2 aggregates are dynamic structures
To visualize the formation of protein inclusions, we car-
ried out a time-lapse microscopy imaging of Neuro2A
cells transfected with pFeGFP-hUBQLN2WT or pFeGFP-
hUBQLN2P497H. A two hours imaging study carried out
at 24 h after transfection revealed the dynamic nature of
aggregates in hUBQLN2 transfected cells. Figure 4c
shows merging aggregates over a 2 h period of time in
pFeGFP-hUBQLN2P497H cells. We observed that smaller
inclusions combined with bigger one (Additional file 2:
Movie S1). To further investigate this phenomenon, we
took pictures of fifty FeGFP-hUBQLN2 positive cells at
24 and 48 h and measured each aggregates size. The
mean aggregates sizes were 69.22 ± 4.032 RU in
UBQLN2WT at 24 h and 213.9 ± 12.99 RU at 48 h after
transfection (Fig. 4a, b). Similar results were obtained
with hUBQLN2P497H (77.03 ± 3.70 and 203.1 ± 13.87 at
24 and 48 h, respectively). We measured over 200
aggregates in each group and did not see significant
difference in the number of aggregates per cell. The
size difference between 24 h and 48 h was significant
(p < 0.0001). We were also able to observe formation
of aggregates after few hours of transfection, confirm-
ing that hUBQLN2 is prone to aggregation [4]. We
also measured aggregates size when transfected with
pCMV-hUBQLN2 (without GFP tag) and similar results
were obtained. Aggregates merged and became bigger
over time after transfection. These results suggest that,
like stress granules, hUBQLN2 inclusions are dynamic in
neurons and they can sequester TDP-43 in the cytosol.
UBQLN2 up-regulation enhances vulnerability to
NF-κB-mediated neuronal death and causes an ER-stress
To further examine whether aggregates of both
hUBQLN2WT and hUBQLN2P497H are associated with
cellular stress with ensuing neuronal death, we moni-
tored cell survival and apoptosis after UBQLN2 transfec-
tion. In ALS spinal cord, there is evidence of inverse
correlation between ubiquitinated inclusions and the
number of motor neurons, suggesting a link between
aggregates and cell toxicity [29]. Moreover, NF-κB
Fig. 3 hUBQLN2 co-localized with TDP-43 and P62 but not with NF-κB and IκB-α. Immunofluorescence of Neuro2A cells at 48 h after transfection
with (a) control plasmid, (b) pCMV-hUBQLN2WT and (c) pCMV-hUBQLN2P497H. Indicated antibodies were used according to Materials and Methods.
Microscopy pictures were taken at 63× magnification. d-e Western analysis from three repeated experiments was used for quantification of
(d) TDP-43 level (p = 0.0227 for hUBQLN2WT and p = 0.0032 for hUBQLN2P497H) and (e) p62 level (p = 0.0058 for hUBQLN2WT and p = 0.0130
for hUBQLN2P497H) in insoluble fraction. Results were calculated in fold change compared to proteins level in insoluble fraction of control
cells. f Neuro2A cells were transfected with control plasmid, pCMV-hUBQLN2WT or pCMV-hUBQLN2P497H. Cells were extracted 48 h after
transfection using aggregates assay protocol. The results suggested that overexpression of UBQLN2 species increased levels of UBQLN2, TDP-43 and
p62 in the insoluble fraction. g Live imaging was performed on Neuro2A pFeGFP-hUBQLN2P497H and DsRED-TDP-43 co-transfected cells. Microscopy
pictures were taken at 24 and 48 h after transfection. h Immunoblot of TDP-43 in cytoplasmic (C) vs nuclear (N) after transfection with
control plasmid, pCMV-hUBQLN2WT or pCMV-hUBQLN2P497H plasmids. i HEK293 cells and Neuro2A cells were transfected with either control plasmid
or pCMV-hUBQLN2P497H plasmid. Protein levels of hUBQLN2 and mUBQLN2 were measured at 48 h after transfection. Human UBQLN2 levels were
similar in control HEK293 and pCMV-hUBQLN2P497H Neuro2A transfected cells. Scale bar = 25 μm
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activation induced by TNF-α was found to induce motor
neuron death in context of glutamate excitotoxicity [30].
Neuro2A cells were transfected with control plasmid
vector, pCMV-hUBQLN2WT and pCMV-hUBQLN2P497H
vectors. We then examined the activation of caspase-3, a
marker of apoptosis. We observed that cleaved-Caspase-
3 was increased in UBQLN2WT (p = 0.039) and
UBQLN2P497H (p = 0.0167) transfected and TNF-α-
treated cells after 48 h compared with control cells
(Fig. 5a, b). Immunofluorescence microscopy showed
that UBQLN2 positive cells were also positive for
caspase-3 (Fig. 5f-h). We performed a MTS assay in
transfected cells at 48 h. The number of viable cells were
decreased in both UBQLN2WT (p = 0.0144) and
UBQLN2P497H (p = 0.0067) transfected cells (Fig. 5i).
To assess the contribution of NF-κB activation to neur-
onal death of UBQLN2 overexpressed cells, we treated the
cells with Withaferin A (WA), a known NF-κB inhibitor
[31]. Neuro2A cells were pre-treated with WA 0.5 μM for
2 h previous to TNF-α 20 ng/ml treatment. First, we ob-
served in luciferase assay of non-transfected cells that WA
decreased NF-κB activity by 2.5 times (p < 0.0001) (Fig. 5e).
Again, we performed a MTS assay in transfected and WA
treated cells and observed that Withaferin A succeeded to
decreased mortality previously found in Neuro2A trans-
fected cells (Fig. 5i). These results suggested that UBQLN2
enhanced vulnerability to neuronal death caused by TNF-
α-mediated NF-κB activation.
We also looked at upstream caspase activation to clar-
ify cellular mechanisms under this apoptosis induction.
Fig. 4 hUBQLN2 inclusions were dynamic. a Immunofluorescence of GFP-labeled hUBQLN2 proteins at 24 h and 48 h after transfection of Neuro2A
cells with pFeGFP-hUBQLN2WT or pFeGFP-hUBQLN2P497H was used to measure the size of inclusions (>200 aggregates, p < 0.0001). Fifty cells per group
were examined. b Immunofluorescence showing representative pictures at each time point (magnification at 63×). c Live imaging was done
on Neuro2A pFeGFP-hUBQLN2P497H transfected cells. Pictures were taken each minute over a 2 h period starting at 24 h post-transfection.
Red arrow is showing moving aggregates (Additional file 2: Move S1). Scale bar = 25 μm
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Cleaved-caspase-12, responsible for ER-stress-induced
apoptosis, was increased in hUBQLN2WT (p = 0.0023)
and hUBQLN2P497H (p = 0.0309) transfected cells (Fig. 5a
and c). It has been shown that UBQLN2 mutation leads
to proteasome impairment [4] and impairs endoplasmic
reticulum-associated protein degradation (ERAD) [32].
Normally, ER proteins which fail to fold correctly are de-
graded by the 26S proteasome but when proteasome is
impaired, ER stress is induced by the accumulation of
ERAD substrates [33]. To confirm if the caspase-12 in-
crease can be explain by UBQLN2-mediated ER-stress,
we quantified ER-stress markers.
Protein aggregates causing ER-stress leads to increased
levels of Binding immunoglobulin protein (BiP), an ER
chaperone. In circumstance of accumulation of unfolded
proteins in the ER, BiP induces activation of different
transmembrane proteins like protein kinase RNA-like
endoplasmic reticulum kinase (PERK) or Activating
transcription factor 6 (ATF6). BiP levels were increased
in hUBQLN2WT and in hUBQLN2P497H transfected
Neuro2A (Fig. 5d). ATF6 is a membrane-anchored key
transcription factor of the unfolded protein response
(UPR) [34]. We observed an increase in cleaved frag-
ment of ATF6 (36 kDa) in both hUBQLN2WT and
hUBQLN2P497H. Phospho-PERK was also increased in
UBQLN2 transfected cells. From these results, we can
postulate that UBQLN2 aggregates (unfolded proteins)
and ERAD degradation impairment [32] lead to BiP acti-
vation and BiP induced an ER-stress response.
Discussion
Here, we report that an upregulation of Ubiquilin-2 spe-
cies can enhance NF-κB activity in neuronal cells. Many
lines of evidence support this conclusion: (a) nuclear
levels of NF-κB phospho-P65 were increased in Neuro2A
cells overexpressing hUBQLN2WT and hUBQLN2P497H,
and after TNF-α treatment (Fig. 1a, b); (b) luciferase re-
porter activity of NF-κB was also increased in cells overex-
pressing hUBQLN2WT or hUBQLN2P497H (Fig. 1c, d); and
(c) down-regulation of hUBQLN2 by the use of siRNA
targeting hUBQLN2 succeeded in reducing NF-κB activity
to its basal level (Fig. 1e). So, we detected significant
increase of NF-κB activity by UBQLN2 species up-
regulation using three different approaches. It should be
noted that an up-regulation of UBQLN2 alone was not
sufficient to activate NF-κB and that Neuro2A cells re-
quired to be primed with TNF-α.
These results are consistent with the view of a conver-
ging role for NF-κB in ALS pathogenesis. Several ALS-
linked proteins were found to modulate the NF-κB path-
way: TDP-43 upregulation can enhance NF-κB activation
[14], mutation in valosin-containing protein (VCP) in
mice resulted in NF-κB hyperactivation [35, 36] and sup-
pression of Optineurin (OPTN) led to neuronal death
via NF-κB pathway [37]. Fuse in Sarcoma (FUS) was
found to enhance NF-κB activation induced by
physiological stress [38] and NF-κB-related inflamma-
tion was increased in mouse deficient in Progranulin
(PGRN) [39]. Furthermore, there are reports that NF-κB
Fig. 5 UBQLN2 induced a NF-κB-mediated neuronal cell death and an ER-stress response. a Neuro2A cells were transfected with control plasmid,
pCMV-hUBQLN2WT or pCMV-hUBQLN2P497H and collected after 48 h including 4 h TNF-α 20 ng/ml treatment, (C) cytoplasmic and (N) nuclear.
Quantification of (b) cleaved-caspase-3 (n = 3) and (c) caspase-12 (n = 3) vs GAPDH as compared to cytoplasmic level in control cells when treated
with TNF-α. (d) Total proteins extract was used for western analysis of ER-stress marker 48 h after transfection of control plasmid pCMV-UBQLN2WT and
pCMV-UBQLN2P497H. (e) Neuro2A cells were stably transfected with pluc2p-NFκB-RE plasmid and then treated with Withaferin A (WA) 0.5 μM for 2 h
previous to TNF-α 20 ng/ml treatment. Luciferase activity (NF-κB) showed a significant decreased in NF-κB activity after WA treatment (n = 3,
p < 0.0001). (f-h) Immunofluorescence of Neuro2A-transfected cells fixed in PFA 4 % at 48 h and then labeled with cleaved caspase-3 (green)
and flag (UBQLN2) (red) in (e) control transfected cells (f) hUBQLN2WT-transfected cells and (g) hUBQLN2P497H-transfected cells. Scale bar = 25 μm.
(i) MTS assay was realized on cells at 48 h after transfection. The number of live cells was represented using percentage of live cell as
compared to control transfected cells. We observed significant mortality in hUBQLN2WT (p = 0.0144, n = 3) and hUBQLN2P497H (p = 0.0067,
n = 3) transfected cells. Cells were also treated with Withaferin A 0.5 μM for 2 h previous to TNF-α 20 ng/ml treatment
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inhibition by Withaferin A conferred neuroprotection in
transgenic mouse models [14, 15].
Our findings that an up-regulation of UBQLN2 species
enhances NF-κB activity in a TNF-α treatment
dependent manner (Fig. 1) led us to investigate the cel-
lular mechanisms underlying this activation. Evidence
for MAPK implication came from the observation that:
(a) phospho-p38 MAPK levels were increased in cells
transfected with UBQLN2 species mainly with TNF-α
treatment (Fig. 2a and d) and (b) there was inhibition of
NF-κB activation due to UBQLN2 species by treatment
with p38 inhibitor but not with p42/44 or JNK inhibitors
(Fig. 2g, h). Thus, our results suggest an involvement of
p38 MAPK in the enhancement of NF-κB activation by
UBQLN2. Figure 2b is showing a hypothetical model of
NF-κB activation by UBQLN2 inclusions. Because
phospho-p38 MAPK was robustly increased in UBQLN2
overexpressing cells and because its inhibitor SB203580
blocked a significant increase of NF-κB activity in
UBQLN2 species-transfected Neuro2A cells, we propose
that p38 is the main activator of NF-κB p65 due to
UBQLN2 overexpression. This is the first report of NF-κB
activation via p38 MAPK pathway by an up-regulation of
ALS-linked UBQLN2 mutant. This finding is in line with
previous reports of up-regulation of p38 MAPK levels in
motor neurons of SOD1G93A mice [40, 41].
A common pathological feature of ALS/FTD is the re-
distribution of TDP-43 from nucleus to cytoplasm in
neurons of spinal cord and brain [42]. Here, we report
that physiological (Fig. 3i) expression of hUBQLN2WT
or hUBQLN2P497H in Neuro2A can promote formation
of cytoplasmic inclusions that progressively sequester
TDP-43. The evidence is based on the immunolocaliza-
tion of UBQLN2 and TDP-43 (Fig. 3a, c), the increased
TDP-43 levels in insoluble fraction of Neuro2A trans-
fected with UBQLN2WT and UBQLN2P497H (Fig. 3d, e, f )
and the increased levels of TDP-43 in the cytosol of
Neuro2A cells overexpressing UBQLN2 species (Fig. 3h).
These results are consistent with previous reports that
ALS patients with UBQLN2 mutation are exhibiting
UBQLN2 aggregates positives for TDP-43 [4, 5] and that
UBQLN2 binds TDP-43 with high affinity [43]. A co-
localization of either UBQLN2WT or UBQLN2P497H with
c-TDP-43 has also been shown in Neuro2A cells co-
transfected with c-TDP-43 and UBQLN2 [4] but not in
UBQLN2P497H transgenic mouse [27] or in UBQLN2P497H
transgenic rats [28]. This inconsistency can be explained
by the low to moderate level of UBQLN2 protein in these
in vivo models. It has been proposed that interaction and
aggregation between UBQLN2 and TDP-43 is concentra-
tion dependent [4, 43]. Indeed, we noted that TDP-43 was
easier to detect in UBQLN2 aggregates at 48 h than 24 h
after transfection which correlate to UBQLN2 aggregates
sizes (Fig. 3g-4a).
So, factors in ALS which may contribute to cytosolic
accumulation of UBQLN2 such as proteasome defi-
ciency [4, 44] might also contribute to cytosolic TDP-43
accumulations. The early pathogenic mechanisms under-
lying TDP-43 recruitment to UBQLN2 inclusions has to
be clarified. Recent report suggested that the binding of
UBQLN2 to the C-terminal tail of TDP-43 reduces
TDP-43 affinity for nucleic acids and may inhibit its
physiologic function and increase its aggregation [43].
Another study has suggested that the oxidation of
RRM1 domain of TDP-43 may cause protein aggregation
[45]. Although, there is substantial evidence for oxidative
stress in ALS physiopathology [46], it is still unknown
whether UBQLN2 aggregation can cause oxidative stress
which lead to TDP-43 RRM1 domain oxidation. How-
ever, we report that UBQLN2 up-regulation cause a
cellular stress which leads to MAPK activation. Interest-
ingly, kinases have been recently shown to have a critical
role in TDP-43 accumulation in stress granules follow-
ing a chronic stress [47]. The phosphorylation by kinases
may modulate the association of TDP-43 with stress
granules and, through a chronic process, could lead to
the pathogenic aggregates find in ALS. Consequently, a
time dependent recruitment of TDP-43 in UBQLN2 in-
clusions (Fig. 3g) could be explained in part by chronic
kinases activation caused by UBQLN2 dysregulation.
We propose that UBQLN2 overexpression increased
vulnerability to neuronal death. Many lines of evidence
support this conclusion: (a) protein levels of cleaved
caspase-3 and caspase-12, an ER-stress related caspase,
were increased in cells overexpressing UBQLN2 species
when treated with TNF-α (Fig. 5a); (b) most of cleaved
caspase-3 positive cells were positive for UBQLN2
(Fig. 5f, h); and (c) the number of living cells counted by
MTS assay were decreased in Neuro2A transfected with
UBQLN2WT or UBQLN2P497H (Fig. 5i). Moreover, we
observed that UBQLN2-induced neuronal death can be
decreased with WA treatment (Fig. 5i), which could sug-
gest a role for NF-κB activation in neuronal death. We
have previously shown that TDP-43 overexpression can
enhance microglial toxicity toward neighboring neu-
rons via NF-κB pathway and that NF-κB inhibition by
Withaferin A treatment of TDP-43 mouse model re-
duces ALS disease symptoms [14]. Withaferin A also
reduced levels of misfolded SOD1 and extended life-
span of mutant SOD1 ALS mice [15]. NF-κB is also
known to modulates apoptosis in neurons treated with
glutamate [48] or with chemicals inducing DNA-
damage [49]. Our results are similarly consistent with
previous studies with UBQLN2P497H rats reporting
neuronal loss in the cortex and dentate gyrus and a
glial activation surrounding neuronal damages [28].
These results, taken together, suggest that the up-
regulation of UBQLN2 species can act like TDP-43
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toxicity in neurons and that neurons bearing UBQLN2
inclusions become more vulnerable to toxic mediator
TNF-α secreted by activated microglia in context of
inflammation.
There is evidence that mutations in UBQLN2 can slow
down degradation of this protein [4, 44]. Thus, such im-
pairment of protein turnover can lead to an increase in
the steady state levels of mutant UBQLN2. A similar
post-transcriptional dysregulation in levels of WT
UBQLN2 in ALS cases without genetic mutation cannot
be excluded. Indeed, UBQLN2 accumulations have been
detected in ALS patients without a mutation in the
ubiquilin-2 gene [4]. Our observation that both WT and
mutant UBQLN2 species can form inclusions when
overexpressed in transfected Neuro2A cells (Fig. 3) are
in line with data previously reported by Deng et al. [4].
Conclusion
In conclusion, our results suggest that dysregulation by
up-regulation of UBQLN2 may contribute in part to
sporadic and familial ALS pathogenesis through en-
hancement of NF-κB activation by p38 MAPK signaling
and formation of inclusion bodies sequestering TDP-43.
These pathways might represent suitable therapeutic
targets for future ALS treatment.
Methods
Cell culture, transfection and cell treatment
Almost all experiments were done with Neuro2A cells,
which are mouse neuroblastoma cells. Neuro2A cells
were growth in Dulbecco’s Modified Eagle Medium
(DMEM) with 10 % fetal bovine serum (FBS), 1 %
penicillin-streptomycin and 1 % glutamine. Cells were
transfected at 80-90 % confluence with lipofectamine
2000 according to manufacturer protocol. Opti-MEM
media was replaced by normal growth media 24 h
after transfection. PCMV-hUBQLN2WT and pCMV-
hUBQLN2P497H were used for transfection (see sec-
tion plasmids construction). We used pCDNA3 as control
plasmid. Cells were collected at 24 h or 48 h after
transfection consistent with the experiment. Recom-
binant mTNF-α (R&D systems, Minneapolis) treat-
ment (20 ng/ml) was done 4 h before collecting the
cells. HEK293 cells, which are human embryonic kid-
ney cells, for Fig. 3i were cultured with same protocol
as Neuro2A.
For kinase pathways investigation, MAPK specific inhib-
itors U0126-EtOH, SP600125 and SB203580 (ApexBio,
Houston) dissolved at 1 mg/ml in DMSO were used at
10 μM in a 1 h pre-treatment and then TNF-α (20 ng/ml)
was added to the cells for 4 h. Human UBQLN2 siRNAs
were purchased from Origene (catalog No: SR309321,
Rockville). SiRNA SR309321A: rGrGrCrArGrCrUrCrAr
UrUrArUrGrG rCrUrArArUrCrCrACA was used for the
experiments. Cells were co-transfected with siRNA
(10 nM) and control plasmid, pCMV-hUBQLN2WT or
pCMV-hUBQLN2P497H. NF-κB activation (luciferase
assay) was measure at 48 h after transfection and
after 4 h TNF-α treatment.
Protein extraction and Western blot analysis
After collecting the cells, cytoplasmic and nuclear ex-
traction or total proteins extraction was realized. Cyto-
plasmic buffer contained 10 mM HEPES pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10 % glycerol,
1 mM PMSF, 10 mM NaF and 1 mM Na2VO3. After ice
lysis and low speed centrifugation, nuclear fraction was
obtained with sonication in buffer containing 3 mM
EDTA, 0.2 mM EGTA, 1 mM PMSF, 10 mM NaF, 1 mM
Na2VO3. 30 μg of proteins was loaded into 10 % SDS-
page gels. Total protein was obtained with buffer
containing 0.15 M NaCl, 0.05 M tris pH 7.4, 10 %
glycerol and 1 % Triton X-100. Cells were incubated on
ice for 30 min and then centrifuged to collect the
supernatant.
For aggregates assay, we first collected the cells at 48 h
after transfection and dissolved them into a re-
suspending buffer containing 10 mM tris, 1 mM EDTA
and 100 mM NaCl. Then, we added same volume of ex-
traction buffer 1 containing 10 mM Tris, 1 mM EDTA,
100 mM NaCl, 1 % NP-40, protease and phosphatase in-
hibitor 1X. After sonication and high speed centrifuga-
tion (>100 000 g) for 5 min, we kept the supernatant
(soluble fraction). We added extraction buffer 2 contain-
ing 10 mM Tris, 1 mM EDTA, 100 mM NaCl, 0,5 %
NP-40 and protease and phosphatase inhibitor 1X to the
pellet 1, sonicated and centrifuged again (>100 000 g for
5 min). After removing the supernatant, we extracted
the pellet 2 with 10 mM Tris, 1 mM EDTA, 100 mM
NaCl, 0,5 % NP-40, 0,25 % SDS, 0,5 % Deoxycholic acid
and phosphatase and protease inhibitor 1X. Finally, we
sonicated and kept supernatant 3 (insoluble fraction) [50].
Antibodies used were phospho-NF-κB p65 (Cell sig-
naling, Whitby, 1:1000), NF-κB p65(Santa-cruz, Dallas,
1:1000), phospho-IκB-α (Cell signaling, 1:1000), IκB-α
(Santa-Cruz, 1:1000), actin (Milipore, Etobicoke,
1:20,000), p84 nuclear matrix (Abcam, Cambridge,
1:1000), GAPDH (Abcam, 1:1000), TARDBP (Proteintech,
Chicago, 1:2500), FLAG M2 (Sigma-Aldrich, Saint-Louis,
1:1000), UBQLN2 (Abcam, 1:1000), phospho-SAPK/JNK
(Cell signaling, 1:1000), SAPK/JNK (Cell signaling,
1:1000), phospho-p42/44 (Cell signaling, 1:1000), p42/44
(Cell signaling, 1:1000), phospho-p38 (Cell signaling,
1:1000) p38 (Cell signaling, 1:1000), cleaved-caspase-3
(Cell signaling, 1:1000), caspase-12 (Cell signaling,
1:1000), phospho-PERK (Cell signaling, 1:1000), PERK
(Sigma-Aldrich, 1:1000), ATF6 (Imgenex, 1:1000) and BiP
(Cell signaling, 1:1000).
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Luciferase assay
Neuro2a cells were stably transfected with pGL4.32
[luc2p/NF-κB-RE/Hygro] (Promega, Madison) and then
transfected with previous plasmids. After 24 or 48 h,
cells were lysed with glo lysis buffer (Promega, Madison)
and 1 volume of Bright Glo luciferase assay system
(Promega, Madison) was added after 5 min. Each
sample was duplicated and the experiments were re-
peated more than 5 times. Luciferase activity was
measured with Enspire reading machine in a 96 wells
plate.
Immunofluorescence
48 h after transfection with pCMV-UBQLN2WT and
pCMV-UBQLN2P497H, cells were fixed with 4 % PFA
and methanol on 10 mm coverslip. Goat serum 10 %
was used for blocking. First antibody was incubated
overnight at 4 °C and 1 h at room temperature for sec-
ondary antibody. Primary antibodies were monoclonal
Flag M2 (Sigma-Aldrich, Saint-Louis, 1:100), TARDBP
(Proteintech, Chicago, 1:600), NF-κB p65 (Santa-Cruz,
1:200), IκB-α (Santa-Cruz, 1:200) and SQSTM1/P62
(Cell signaling, 1:200). Secondary antibodies were alexa-
fluor 488 goat anti-rabbit (1:500) and alexa-fluor 594
goat anti-mouse (1:500).
Plasmids construction
Human UBQLN2 gene was obtained by PCR from RP11
human BAC: 43 N15. Gene was amplified using the
primer 5′GGGGAATT CATGGACTACAAGGACGA
CGATGACAA GGCTGAGAATGGCGAGAGCAGCG
GC-3′ (forward) and 5′-GGGGCGGCCGC TGGGGT
GGGATAATCCTCCTAAAC-3′ (reverse). The forward
primer introduced an EcoRI restriction site and a flag
tag in C-terminal. The reverse primer introduced a NotI
restriction site. The P497H mutation was introduced by
mutagenesis. The PCR products were ligated into
pCDNA3 plasmids with same restriction sites. The plas-
mids finally drove human UBQLN2 wild-type or P497H
mutant c-terminally fused to Flag under the control of a
CMV promoter. We named these two plasmids pCMV-
hUBQLN2WT and pCMV-hUBQLN2P497H.
To create a FeGFP-hUBQLN2 plasmid, we amplified
UBQLN2 sequence from previous pCMV-UBQLN2
plasmids by PCR using the primer 5′-dGGGACGACG
GATCCG CTGAGAATGGCGAGAGCAGCGGCCC-3′
(forward) and 5′-dGGGACGACGCGG CCGCTTAC
GATGGCTGGGAGCCCAG -3′ (reverse). The forward
and reverse primers introduced BamHI and NotI restric-
tion sites without the flag tag in c-terminal. The PCR
product was ligated into pCDNA3-Flag-eGFP plasmid
with the same restriction sites. The plasmids finally
drove human UBQLN2 c-terminally fused to Flag-eGFP
under the control of a CMV promoter. We named these
two plasmids pCMV-FeGFP-hUBQLN2WT and pCMV-
FeGFP-hUBQLN2P497H. Human wild type TDP-43 gene
was used for DsRed-TDP-43 plasmid construction like
previously described [51].
MTS assay
The number of live cells in proliferation was measured by
MTS assay 48 h after transfection. Celltiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Madison)
was a colorimetric assay for determining the cell viability.
MTS tetrazolium compound was reduced in a colored for-
mazan by live cells. Cells were growth in a 24 wells plate.
Live cells were washed with PBS X2 and then collected.
We took 100 μl of media and putted them in a 96 wells
reading plate. 20 μl of One solution Reagent was added
and cells were incubated at 37 °C for 1 h. Absorbance was
measured at 490 nm. Viable cell was calculated by divid-
ing absorbance in transfected cells by absorbance in non-
transfected cells and then reported in percentage of
control transfected cells. Cells were either treated or not
with Withaferin A (Enzo Life Sciences) 0.5 μM for 2 h
and TNF-α 20 ng/ml was added to media for 4 h.
Live cell imaging
Neuro2A cells were transfected with pCMV-FeGFP-
hUBQLN2WT, pCMV-FeGFP-hUBQLN2P497H or DsRed-
TDP-43. After 24 h, opti-MEM was removed and re-
placed by DMEM 10 % FBS. Cells were then putted in
NIKON ECLIPSE TE2000-E live imaging system. Pic-
tures were taken every 2 min over a 2 h period using
Metamorph software.
Statistical analysis
Statistical significance was assessed using GraphPad
Prism software. We used Student’s unpaired t-test for
generating the p-values. We considered p < 0.05 as sta-
tistically significant.
Additional files
Additional file 1: Lack of cytoplasmic inclusions in neuro2A cells
overexpressing TDP-43. Immunofluorescence of Neuro2A cells at 48 h
after transfection with pCMV-TDP-43 vector only. TDP-43 is mainly
expressed in nucleus. No TDP-43 aggregates were detected in cytosol
of transfected cells. Scale bar = 25 μm. (JPEG 1482 kb)
Additional file 2: Movie S1. Movement and fusion of UBQLN2
inclusions in Neuro2A. Live imaging was performed on Neuro2A
pFeGFP-hUBQLN2P497H transfected cells. Pictures of a single cell were
taken each minute over a 2 h period starting at 24 h after transfection
(n = 3). Neuro2A transfected with pFeGFP-hUBQLN2WT display the same
aggregates movement. We observed different aggregates combining
together over this period. Small aggregates seemed to all combined
with the bigger aggregate. (AVI 467717 kb)
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